IconOVir Bio

Iconovir Bio is a preclinical-stage biotechnology company developing next-generation oncolytic virus therapies to improve the treatment of cancer. Oncolytic viruses are viruses that are engineered to kill cancer cells while leaving healthy cells unharmed. Iconovir Bio's oncolytic viruses are designed to be more potent, selective, and persistent than previous generations of oncolytic viruses. The company's viruses are also designed to be less immunogenic, which means that they are less likely to trigger an immune response from the patient. Iconovir's proprietary platform has the potential to develop new and more effective treatments for cancer.

Jobs: